Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Veliparib dihydrochloride (ABT-888 dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 47.00 | |
10 mg | In stock | $ 67.00 | |
25 mg | In stock | $ 119.00 | |
50 mg | In stock | $ 197.00 | |
100 mg | In stock | $ 317.00 | |
200 mg | In stock | $ 517.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 52.00 |
Description | Veliparib dihydrochloride (ABT-888 dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. |
Targets&IC50 | PARP2:2.9 nM(Ki), PARP1:5.2 nM (Ki) |
In vitro | Veliparib demonstrates inactivity towards SIRT2 at concentrations greater than 5 μM[1] and exhibits potent inhibition of PARP activity, with an EC50 of 2 nM in C41 cells[2]. It effectively reduces PAR levels in H460 cells, regardless of irradiation status, and significantly impairs clonogenic survival by hindering DNA repair via PARP-1 inhibition. Additionally, when used in conjunction with radiation, Veliparib promotes apoptosis and autophagy in H460 cells[3]. Its ability to inhibit PARP activity extends to H1299, DU145, and 22RV1 cells, a process not influenced by p53 function. At a concentration of 10 μM, Veliparib diminishes the surviving fraction in clonogenic H1299 cells by 43%, enhancing radiosensitivity, particularly in oxygen-rich environments. Furthermore, it reduces the surviving fraction in H1299, DU145, and 22RV1 cells under hypoxic-irradiated conditions[4], confirming its role in sensitizing cancer cells to radiation by targeting PARP-dependent mechanisms. |
In vivo | Veliparib exhibits an oral bioavailability ranging from 56% to 92% across different species, including mice, SD rats, beagle dogs, and cynomolgus monkeys[1]. At a dosage of 25 mg/kg (i.p.), it enhances tumor growth delay in NCI-H460 xenograft models and, when combined with radiation, decreases tumor vessel formation[3]. Additionally, Veliparib significantly reduces intratumor PAR levels by over 95% at dosages of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models, with this suppression sustained over time[4]. |
Kinase Assay | PARP assays are conducted in a buffer containing 50 mM Tris (pH 8.0), 1 mM DTT, 1.5 μM [3H]NAD+?(1.6 μCi/mmol), 200 nM biotinylated histone H1, 200 nM slDNA, and 1 nM PARP-1 or 4 nM PARP-2 enzyme. Reactions are terminated with 1.5 mM benzamide, transferred to streptavidin Flash plates, and counted using a TopCount microplate scintillation counter. |
Synonyms | ABT-888 dihydrochloride |
Molecular Weight | 317.21 |
Formula | C13H18Cl2N4O |
CAS No. | 912445-05-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.2 mg/mL (10.09 mM)
H2O: 50 mg/mL (157.62 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Veliparib dihydrochloride 912445-05-7 Autophagy Chromatin/Epigenetic DNA Damage/DNA Repair PARP Veliparib poly ADP ribose polymerase ABT 888 Dihydrochloride ABT888 inhibit ABT-888 dihydrochloride ABT-888 Dihydrochloride Inhibitor ABT-888 Veliparib Dihydrochloride ABT888 Dihydrochloride ABT 888 inhibitor